222. 一次性ネフローゼ症候群 [臨床試験数:234,薬物数:241(DrugBank:78),標的遺伝子数:59,標的パスウェイ数:185

Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00001959December 199918/1/2000Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)Pirfenidone in Focal Segmental Glomerulosclerosis:Phase II StudyFibrosis;Focal Glomerulosclerosis;Kidney Failure;Nephrotic Syndrome;ProteinuriaDrug: PirfenidoneNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NULLCompleted18 YearsN/AAll21Phase 2United States